Characteristics of Facilities With Early and Rapid Ustekinumab Adoption for Patients With Inflammatory Bowel Disease.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 37104671.
- Also identified by DOI 10.14309/ajg.0000000000002304 and PMC identifier 10524501.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To examine which facility characteristics, including teamwork, are associated with early or rapid inflammatory bowel disease-related ustekinumab adoption. We examined the association between ustekinumab adoption and the characteristics of 130 Veterans Affairs facilities. Mean ustekinumab adoption increased by 3.9% from 2016 to 2018 and was higher in urban compared with rural facilities (β = 0.03, P = 0.033) and among facilities with more teamwork (β = 0.11, P = 0.041). Compared with nonearly adopters, early adopters were more likely be high-volume facilities (46% vs 19%, P = 0.001). Facility variation in medication adoption provides an opportunity for improving inflammatory bowel disease care through targeted dissemination strategies to improve medication uptake.
Medical subject headings
- Ustekinumab
- Inflammatory Bowel Diseases